Chi Meng Fong
Stock Analyst at Bank of America Securities
(1.63)
# 3,502
Out of 4,983 analysts
43
Total ratings
40%
Success rate
0.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chi Meng Fong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Reiterated: Hold | $37 → $38 | $34.71 | +8.04% | 27 | Aug 31, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $21 → $25 | $18.77 | +33.19% | 5 | Aug 7, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $63 | $43.73 | +44.07% | 1 | Jul 13, 2026 | |
| CCCC C4 Therapeutics | Rated: Hold | n/a | $3.85 | n/a | 5 | Oct 31, 2023 | |
| FHTX Foghorn Therapeutics | Rated: Hold | n/a | $6.00 | n/a | 5 | Oct 6, 2023 |
Roivant Sciences
Aug 31, 2026
Reiterated: Hold
Price Target: $37 → $38
Current: $34.71
Upside: +8.04%
Relay Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $21 → $25
Current: $18.77
Upside: +33.19%
Supernus Pharmaceuticals
Jul 13, 2026
Maintained: Buy
Price Target: $63
Current: $43.73
Upside: +44.07%
C4 Therapeutics
Oct 31, 2023
Rated: Hold
Price Target: n/a
Current: $3.85
Upside: n/a
Foghorn Therapeutics
Oct 6, 2023
Rated: Hold
Price Target: n/a
Current: $6.00
Upside: n/a